As drug target reemerges, the question is to block or stimulate it
As drug target reemerges, the question is to block or stimulate it
About this item
Full title
Author / Creator
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
In a paper published last month, researchers from Spinifex and their collaborators reported the first clinical data on a compound that binds to AT2 called EMA401. Results from the placebo-controlled phase 2 trial suggest that EMA401, which blocks the receptor, can blunt lingering nerve pain due to damage caused by the shingles virus.
Alternative Titles
Full title
As drug target reemerges, the question is to block or stimulate it
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1505250487
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1505250487
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/nm0314-222
